<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04971512</url>
  </required_header>
  <id_info>
    <org_study_id>EDP 721-001</org_study_id>
    <nct_id>NCT04971512</nct_id>
  </id_info>
  <brief_title>A 2 PART STUDY EVALUATING EDP-721 IN HEALTHY SUBJECTS AND EDP-721 IN COMBINATION WITH EDP-514 IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION.</brief_title>
  <official_title>A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP-721 in Healthy Subjects (Part 1) and the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of EDP-721 in Combination With EDP-514 in Patients With Chronic Hepatitis B Virus Infection (Part 2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Enanta Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Enanta Pharmaceuticals</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Part 1 is a randomized, double-blind, placebo-controlled study to evaluate the safety,&#xD;
      tolerability, and pharmacokinetics of single and multiple ascending doses of EDP-721 in&#xD;
      healthy subjects.&#xD;
&#xD;
      Part 2 is a randomized, double-blind, placebo-controlled study to evaluate the safety,&#xD;
      tolerability, pharmacokinetics and antiviral activity of EDP-721 in combination with EDP-514&#xD;
      in patients with chronic hepatitis B virus infection.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2, 2021</start_date>
  <completion_date type="Anticipated">August 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 8 Days in HV SAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 21 Days in HV MAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 70 Days in NUC-suppressed CHB MAD Cohorts</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety measured by adverse events</measure>
    <time_frame>Up to 98 Days in Viremic CHB MAD Cohorts</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-721</measure>
    <time_frame>Up to 6 Days in HV SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-721</measure>
    <time_frame>Up to 6 Days in HV SAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-721</measure>
    <time_frame>Up to 18 Days in HV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-721</measure>
    <time_frame>Up to 18 Days in HV MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-721 alone and in combination with EDP-514</measure>
    <time_frame>Up to 28 Days in All CHB MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-721 alone and in combination with EDP-514</measure>
    <time_frame>Up to 28 Days in All CHB MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax of EDP-514 in combination with EDP-721</measure>
    <time_frame>Up to 28 Days in All CHB MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC of EDP-514 in combination with EDP-721</measure>
    <time_frame>Up to 28 Days in All CHB MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HBV DNA Viral Load Assay</measure>
    <time_frame>Through Day 28 in All CHB MAD Cohorts</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in quantitative HBsAg</measure>
    <time_frame>Through Day 28 in All CHB MAD Cohorts</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Chronic Hepatitis B Virus Infection</condition>
  <arm_group>
    <arm_group_label>EDP-721 HV SAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-721 Dose 1, Dose 2, Dose 3 and Dose 4, in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-721 HV MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-721 Dose 1, Dose 2 and Dose 3, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-721 HV SAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, in one single administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-721 HV MAD Placebo Cohort</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo, once daily for 14 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-721+ EDP-514 HBV MAD Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EDP-721 once daily for 14 days followed by EDP-721+EDP-514 once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EDP-721+ EDP-514 HBV MAD Placebo Cohorts</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo once daily for 42 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-721</intervention_name>
    <description>Oral administration (Part 1)</description>
    <arm_group_label>EDP-721 HV MAD Cohorts</arm_group_label>
    <arm_group_label>EDP-721 HV SAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 1)</intervention_name>
    <description>Placebo to match EDP-721, oral administration (Part 1)</description>
    <arm_group_label>EDP-721 HV MAD Placebo Cohort</arm_group_label>
    <arm_group_label>EDP-721 HV SAD Placebo Cohort</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-721 (Part 2)</intervention_name>
    <description>Oral administration (Part 2)</description>
    <arm_group_label>EDP-721+ EDP-514 HBV MAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 2)</intervention_name>
    <description>Placebo to match EDP-721 (Part 2)</description>
    <arm_group_label>EDP-721+ EDP-514 HBV MAD Placebo Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EDP-514</intervention_name>
    <description>Oral administration</description>
    <arm_group_label>EDP-721+ EDP-514 HBV MAD Cohorts</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Part 2)</intervention_name>
    <description>Placebo to match EDP-514</description>
    <arm_group_label>EDP-721+ EDP-514 HBV MAD Placebo Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Part 1 (HV Population):&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 65&#xD;
             years, inclusive.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinically relevant evidence or history of illness or disease.&#xD;
&#xD;
          -  Pregnant or nursing females.&#xD;
&#xD;
          -  History of febrile illness within 7 days prior to the first dose of study drug or&#xD;
             subjects with evidence of active infection.&#xD;
&#xD;
          -  A positive urine drug screen at screening or Day -1.&#xD;
&#xD;
          -  Current tobacco smokers or use of tobacco within 3 months prior to screening.&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (e.g., gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  History of regular alcohol consumption.&#xD;
&#xD;
          -  Receipt of any vaccine, an investigational agent or biological product within 28 days&#xD;
             or 5 times the t½, whichever one is longer, prior to first dose.&#xD;
&#xD;
        Part 2 (CHB Population)&#xD;
&#xD;
        Inclusion Criteria (Nuc-Suppressed CHB Population)&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 70&#xD;
             years, inclusive&#xD;
&#xD;
          -  HBsAg detectable in serum/plasma at Screening and in the most recent HBsAg&#xD;
             serum/plasma testing at least 6 months previously.&#xD;
&#xD;
          -  HBV DNA levels:&#xD;
&#xD;
               -  A Screening HBV DNA level in serum/plasma that is &lt;LLOQ and&#xD;
&#xD;
               -  No HBV DNA serum/plasma test values ≥LLOQ over the previous 12 months (using an&#xD;
                  approved test)&#xD;
&#xD;
          -  CHB subjects must have been on their prescribed HBV NUC treatment with no change in&#xD;
             regimen for 12 months prior to Screening&#xD;
&#xD;
        Inclusion Criteria (Viremic CHB Population):&#xD;
&#xD;
          -  An informed consent document signed and dated by the subject.&#xD;
&#xD;
          -  Healthy male and female subjects of any ethnic origin between the ages of 18 and 70&#xD;
             years, inclusive&#xD;
&#xD;
          -  HBsAg detectable in serum/plasma at Screening and in the most recent HBsAg&#xD;
             serum/plasma testing at least 6 months previously.&#xD;
&#xD;
          -  HBV DNA levels:&#xD;
&#xD;
               -  For subjects who are HBeAg positive at Screening, a Screening HBV DNA level in&#xD;
                  serum/plasma that is ≥20,000 IU/ml, or&#xD;
&#xD;
               -  For subjects who are HBeAg negative at Screening, a Screening HBV DNA level in&#xD;
                  serum/plasma that is ≥2,000 IU/mL, and&#xD;
&#xD;
               -  For all subjects, no HBV DNA serum/plasma test values &lt;1,000 IU/ml over the&#xD;
                  previous 12 months (using an approved test)&#xD;
&#xD;
          -  CHB subjects must not have been on prescribed anti-HBV treatment, specifically pegIFN&#xD;
             and/or NUC therapy for at least 12 months prior to Screening&#xD;
&#xD;
        Exclusion Criteria (Nuc-Suppressed and Viremic CHB Population):&#xD;
&#xD;
          -  A documented prior diagnosis of cirrhosis&#xD;
&#xD;
          -  Pregnant or nursing females&#xD;
&#xD;
          -  Coinfection with human immunodeficiency virus (HIV), HCV, HDV, HAV, or HEV&#xD;
&#xD;
          -  Chronic liver disease of a non-HBV etiology; coexisting liver or biliary diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enanta Pharmaceuticals, Inc</last_name>
    <role>Study Director</role>
    <affiliation>Enanta Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guy De La Rosa, MD</last_name>
    <phone>857 760 0548</phone>
    <email>gdelarosa@enanta.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>New Zealand Clinical Research Ltd</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>ED Gane, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>August 16, 2021</last_update_submitted>
  <last_update_submitted_qc>August 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>First-in-Human</keyword>
  <keyword>Single Ascending Dose</keyword>
  <keyword>Multiple Ascending Dose</keyword>
  <keyword>Hepatitis B virus</keyword>
  <keyword>HBV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Hepatitis B, Chronic</mesh_term>
    <mesh_term>Herpesviridae Infections</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

